BPC-157
The most discussed repair peptide — and almost only in animal models
Experimental material. Read before using anything from here.
Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.
Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.
Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.
Summary
Short for Body Protection Compound 157. Synthetic 15-amino-acid peptide derived from a sequence identified in human gastric juice in the 1990s. Most of the research is in animal models of tendon, ligament and the digestive tract. It is the repair component most present in the combinations (GLOW, KLOW, Wolverine).
Quick reference
- Routes studied
- Subcutaneous is the most common; oral, IM and IV appear in the literature.
- Schedule format
- The daily total is usually split into one or two doses.
- Measure
- Calculation from vial concentration and U-100 syringe units.
- Status
- Mostly preclinical evidence. Not approved by the FDA (June 2026).
BPC-157 Protocol Formats
| Planning band | Per-dose range | Frequency | Typical context |
|---|---|---|---|
| Low | ~250 mcg | 1×/day | Maintenance / general research planning |
| Standard | ~250 mcg | 2×/day | Most published preclinical protocols and community references |
| High | ~500 mcg | 2×/day | Short-term acute-injury research planning |
BPC-157 Protocol Formats
| Approach | Duration | Review point | Best for |
|---|---|---|---|
| Standard | 4-6 weeks | Week 4 | General research planning |
| Extended | 6–8 weeks | Week 6 | Stubborn-injury research models |
| Long | 8–12 weeks | Week 8 | Slow-remodeling tissue research planning |
BPC-157 Reconstitution Guide
| BAC water added | Concentration | 250 mcg dose volume | 500 mcg dose volume | Doses per vial at 250 mcg |
|---|---|---|---|---|
| 2 mL | 5,000 mcg/mL | 0.05 mL = 5 units | 0.10 mL = 10 units | 40 |
| 3 mL | 3,333 mcg/mL | 0.075 mL = ~7.5 units | 0.15 mL = 15 units | 40 |
BPC-157 Timeline & What to Monitor
| Timeframe | Commonly tracked | Notes |
|---|---|---|
| Days 1-7 | Acute pain reports, injection-site response | Anti-doping rule violation begins immediately for tested athletes. |
| Weeks 1-2 | Range-of-motion and functional self-report in case series | Reflects symptom-level changes, not structural healing. |
| Weeks 4-6 | Tendon and ligament endpoints in animal models | Rodent tendon papers commonly assess at this window. |
| Weeks 6-12 | Extended-cycle community reports | No human RCT covers this duration. |
BPC-157 vs TB-500 vs Wolverine Stack
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Class | 15-amino-acid synthetic pentadecapeptide | Synthetic 17-amino-acid Thymosin Beta-4 fragment |
| Common research focus | Tendon, gut, vessel models; gut-stable for oral research | Cell migration; soft-tissue and muscle models |
| Most common research route | SubQ; oral capsules also used | SubQ; longer dose intervals than BPC-157 |
| Half-life pattern | Short plasma half-life (<30 min) in animal PK studies | Longer signaling-relevant action; less frequent dosing |
| Combined references | Frequently paired with TB-500 in community planning (Wolverine combination) | Same pairing |
| Regulatory status | Removed from FDA Category 2 on April 22, 2026; not approved | Also removed from FDA Category 2 on April 22, 2026; not approved |
Storage and handling
The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.
- Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
- After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
- Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
- Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
- Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
- Cloudy solution, with particles or a color change: discard. There is no recovery.
Lab tests and monitoring
This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.
- Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
- Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
- Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
- Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.
Evidence limits
Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.